Groupe Persavita Inc

Patent-pending (WO2019097434) pharmaceutical eye drops for treating presbyopia and cataracts

  • Stage Product In Development
  • Industry Biotechnology
  • Location Montreal, QC, Canada
  • Currency CAD
  • Founded December 2010
  • Employees 2
  • Incorporation Type C-corp
  • Website persavita.com

Company Summary

Funding sought for a clinical trial (already authorized by Health Canada) for a therapeutic natural product in Covid-19.
The project logistics and CROs are ready to help in the conduct of the study, across Canada, decentralized online.
Our experimental natural health product has potent anti-inflammatory properties and may help outpatients with mild to moderate symptoms to avoid hospitalization, alleviate the burden on our health care system.

Team

  • Dr Mahmood Piraee
    CEO

    Mahmood Piraee is a registered pharmacist (Quebec, Canada) with a PhD in molecular and cellular biology from Dalhousie University, Halifax. He has over 20 years of experience in natural products drug discovery and development at international biotechnology companies in Montreal, Canada and Cambridge, United Kingdom. Mahmood strives to help people with science-based patented products.

  • Mahmood Piraee
    President

    - Natural products drug discovery
    - Community pharmacist in Montreal, Quebec

Advisors

  • Dr John Dixon
    Unconfirmed

Previous Investors

  • Invested by founders only
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free